Rich variety of herbal products and health news
Swansea University research into the threat posed by antifungal drug resistance has been highlighted in two prestigious international journals. Fungal disease now kills more people than malaria or TB and the Centre for Disease Control in the USA recognises emergence of multi-drug resistance in fungi as a high level threat. Dr Josie Parker and Prof […]
Continue ReadingA study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer’s disease is the most common form of dementia, making up 60 to 70 per cent of dementia cases. Of all activities with neuroplastic benefits, language use is the most sustained, consuming the largest proportion of time within […]
Continue ReadingThe experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to a new study from National Institutes of Health scientists. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected. The new report from NIH’s […]
Continue ReadingNovartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is a MET inhibitor being evaluated as a treatment for first-line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer (NSCLC)(1). If […]
Continue ReadingGlioblastomas are relentless, hard-to-treat, and often lethal brain tumors. Yale scientists have enlisted a most unlikely ally in efforts to treat this form of cancer – elements of the Ebola virus. “The irony is that one of the world’s deadliest viruses may be useful in treating one of the deadliest of brain cancers,” said Yale’s […]
Continue ReadingBayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an international service provider for clinical studies, laboratory services and contract manufacturing with several sites and clinics in Germany and France. The strategic partnership will lay the foundation for a […]
Continue ReadingTherapeutic cancer vaccines were first developed 100 years ago and have remained broadly ineffective to date. Before tangible results can be achieved, two major obstacles must be overcome. Firstly, since tumor mutations are unique to each patient, cancer cell antigens must be targeted extremely precisely, which is very hard to achieve. Secondly, a safe system […]
Continue Reading11 – 12 May 2020, London, UK. SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference 2020 (HPAPI 2020) coming to London on the 11th – 12th May 2020. The conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease […]
Continue ReadingIt’s no coincidence that some of the worst viral disease outbreaks in recent years – SARS, MERS, Ebola, Marburg and likely the newly arrived 2019-nCoV virus – originated in bats. A new University of California, Berkeley, study finds that bats’ fierce immune response to viruses could drive viruses to replicate faster, so that when they […]
Continue ReadingThe Sanofi Phase 2b study evaluating its investigational BTK (Bruton’s tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieved its primary endpoint. In the trial, SAR442168 significantly reduced disease activity associated with multiple sclerosis (MS) as measured by magnetic resonance imaging (MRI).
Continue Reading